SCHEMBL2662460

SCHEMBL2662460

CCCCN1Cc2nc3c(Br)cccc3c(N)c2C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 2/20 0.38
▸ HRH4 Q9H3N8 1/20 0.37
▸ LMNA P02545 3/20 0.35
▸ PARP1 P09874 2/20 0.35
▸ PARP2 Q9UGN5 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ ALDH1A1 P00352 5/20 0.35
▸ KDM4E B2RXH2 4/20 0.35
▸ MITF O75030 1/20 0.35
▸ ALPG P10696 1/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ PDE5A O76074 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ PTK2B Q14289 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655615 0.93 LMNA (0.41) GRM2HRH4LMNAPARP1PARP2
SCHEMBL2657499 0.89 HRH4 (0.38) GRM2HRH4ALDH1A1KDM4EHPGD
SCHEMBL2655216 0.82 HRH4 (0.42) HRH4PARP1ALDH1A1KDM4EHPGD
SCHEMBL9685810 0.81 LMNA (0.39) LMNAPARP1PARP2HTTALDH1A1
SCHEMBL9684592 0.81 PARP1 (0.42) HRH4LMNAPARP1PARP2HTT
SCHEMBL9684714 0.81 LMNA (0.38) LMNAPARP1PARP2HTTALDH1A1
SCHEMBL2657022 0.80 LMNA (0.41) LMNAPARP1PARP2HTTALDH1A1
SCHEMBL2661894 0.79 HSP90AA1 (0.35) LMNAPARP1PARP2HTTALDH1A1
SCHEMBL2655999 0.79 MEN1 (0.40) LMNAHTTKDM4EPDE5AGAA
SCHEMBL10395363 0.79 LMNA (0.40) LMNAPARP1PARP2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GRM2 316/4885HRH4 167/4885LMNA 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback